Keywords: b-ms, file, vanlev, approval, year-end, bristol-myers, squibb
B-MS to file for Vanlev approval by year-end
Article | 11 November 1999
Bristol-Myers Squibb's new antihypertensive Vanlev (omapatrilat), avasopeptidase inhibitor, outperformed both Pfizer's top-selling calcium channel blocker Norvasc (amlodipine) and AstraZeneca's ACE ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
